Ken is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute. His research has pioneered understanding of the tumor microenvironment in multiple myeloma, and he played a central role in the bench to bedside translation and regulatory approval of new treatments which have markedly improved patient outcome in myeloma. He is a member of the National Institute of Medicine and the Royal Colleges of Physicians and Pathologists (UK), and received the American Society for Clinical Oncology, David Karnofsky Award, the American Association for Cancer Research Joseph Burchenal Award, the William Dameshek Prize from the American Society of Hematology, and the American Cancer Society Medal of Honor in Science. He received his M.D. from Johns Hopkins Medical School, where he also trained in internal medicine, and completed hematology, medical oncology and tumor immunology training at Dana-Farber Cancer Institute. He is a past President of the International Myeloma Society, and of the American Society of Hematology. Ken is a co-founder of C4 Therapeutics.